Related Experiment Video

Updated: Jun 13, 2026

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
08:26

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Published on: January 21, 2020

Sirolimus-eluting stents versus paclitaxel-eluting stents in patients with chronic renal insufficiency

Asmir I Syed1, Itsik Ben-Dor, Sara D Collins

  • 1Division of Cardiology, Department of Medicine, Washington Hospital Center, Washington, DC 20010, USA.

Journal of Interventional Cardiology
|May 15, 2010
PubMed

Insights

Sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) show similar outcomes for patients with chronic renal insufficiency (CRI) undergoing coronary intervention. Both stent types demonstrated acceptable stent thrombosis rates, but high rates of major adverse cardiac events persist.

Area of Science:

  • Cardiology
  • Nephrology
  • Interventional Cardiology

Background:

  • Chronic renal insufficiency (CRI) increases risks of restenosis and stent thrombosis.
  • Drug-eluting stents (DES) are preferred over bare metal stents (BMS) in CRI patients to reduce restenosis.
  • Comparison of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in CRI patients is crucial for clinical decision-making.

Purpose of the Study:

  • To compare the clinical outcomes of SES versus PES implantation in patients with CRI undergoing coronary intervention.
  • To evaluate differences in restenosis, stent thrombosis, and major adverse cardiac events (MACE) between SES and PES in this high-risk population.

Main Methods:

  • A cohort study involving 570 patients with CRI who received either SES (346) or PES (224).
  • Clinical events were tracked for up to 1 year post-intervention.
  • Statistical analysis was performed to compare outcomes between the SES and PES groups, including covariate adjustment.

Main Results:

  • Baseline and procedural characteristics were similar between SES and PES groups.
  • Overall rates of MACE and stent thrombosis were comparable.
  • The PES group showed lower revascularization rates, but this difference was not significant after covariate adjustment. The number of diseased vessels was the strongest predictor of death and MACE.

Conclusions:

  • Both SES and PES provide similar repeat revascularization rates and acceptable stent thrombosis rates in patients with CRI undergoing percutaneous coronary intervention (PCI).
  • Despite advances in stenting, patients with CRI continue to experience high rates of MACE and death.
  • Further research is needed to mitigate long-term adverse outcomes in this vulnerable patient group.
Abstract

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Renal Drug Clearance: Comparison Between Renal Excretion Methods01:08

Renal Drug Clearance: Comparison Between Renal Excretion Methods

Renal clearance is a critical parameter encompassing kidney filtration, secretion, and reabsorption processes. It is calculated using a specific equation to determine the rate at which the kidneys clear a drug.
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...